Class Action Filed Against Humacyte, Inc. Over Alleged Securities Violations

Investors Urged to Act Before Class Period Deadline

LOS ANGELES, Dec. 23, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, is notifying investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) HUMA for breaking §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 established by the U.S. Securities and Exchange Commission.

Investors who bought the Company’s securities from May 10, 2024, to October 17, 2024, inclusive (the “Class Period”), should reach out to the firm by January 17, 2025.

If you’ve experienced a loss as a shareholder, click here to join the case.

Additionally, contact Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, by calling 310-301-3335 for a free consultation about your rights. You can also visit the firm’s website at www.schallfirm.com, or email at bschall@schallfirm.com.

Currently, the class has not been certified, meaning you are not yet represented by an attorney. Should you choose not to act, you will remain an absent class member.

The Complaint states that Humacyte made false and misleading statements that affected the market. The Company reportedly did not maintain proper manufacturing practices, and microbial testing at its Durham, North Carolina facility was inadequate. Consequently, the FDA delayed the review of its Biologic License Application (BLA) while the Company addressed these manufacturing issues. These setbacks could impact the FDA’s timely approval of the acellular tissue engineered vessel (“ATEV”) intended for vascular trauma. Thus, throughout the class period, Humacyte’s public statements were considered false and misleading, resulting in losses for investors once the truth was disclosed.

Join this case to recover your losses.

The Schall Law Firm serves investors worldwide and focuses on securities class action lawsuits and shareholder rights litigation.

This release may fall under Attorney Advertising laws in certain jurisdictions.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

View original content to download multimedia: here.

SOURCE The Schall Law Firm